CytomX Therapeutics Valuation
| CTMX Stock | USD 0.80 0.03 3.61% |
Today, the firm appears to be undervalued. CytomX Therapeutics shows a prevailing Real Value of $1.76 per share. The current price of the firm is $0.8. Our model approximates the value of CytomX Therapeutics from analyzing the firm fundamentals such as Profit Margin of 0.11 %, current valuation of (44.67 M), and Return On Equity of -54.75 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting CytomX Therapeutics' valuation include:
Price Book 5.0363 | Enterprise Value | Enterprise Value Ebitda 3.8585 | Price Sales 0.4922 | Forward PE 14.2045 |
Undervalued
Today
Please note that CytomX Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of CytomX Therapeutics is based on 3 months time horizon. Increasing CytomX Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since CytomX Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CytomX Stock. However, CytomX Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.8 | Real 1.76 | Target 4.69 | Hype 0.8 |
The intrinsic value of CytomX Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence CytomX Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of CytomX Therapeutics helps investors to forecast how CytomX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CytomX Therapeutics more accurately as focusing exclusively on CytomX Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use CytomX Therapeutics' intrinsic value based on its ongoing forecasts of CytomX Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against CytomX Therapeutics' closest peers.
CytomX Therapeutics Cash |
|
CytomX Valuation Trend
Analysing the historical paterns of CytomX Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of CytomX Therapeutics over time and is usually enough for investors to make rational market timing decisions.
CytomX Therapeutics Total Value Analysis
CytomX Therapeutics is currently expected to have valuation of (44.67 M) with market capitalization of 62.32 M, debt of 13.97 M, and cash on hands of 194.29 M. The negative valuation of CytomX Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the CytomX Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(44.67 M) | 62.32 M | 13.97 M | 194.29 M |
CytomX Therapeutics Investor Information
About 60.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years. Based on the key indicators related to CytomX Therapeutics' liquidity, profitability, solvency, and operating efficiency, CytomX Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.CytomX Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. CytomX Therapeutics has an asset utilization ratio of 50.16 percent. This suggests that the Company is making $0.5 for each dollar of assets. An increasing asset utilization means that CytomX Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.CytomX Therapeutics Ownership Allocation
CytomX Therapeutics holds a total of 78.26 Million outstanding shares. Over half of CytomX Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.CytomX Therapeutics Profitability Analysis
The company reported the previous year's revenue of 101.21 M. Net Loss for the year was (569 K) with profit before overhead, payroll, taxes, and interest of 126.62 M.About CytomX Therapeutics Valuation
Our relative valuation model uses a comparative analysis of CytomX Therapeutics. We calculate exposure to CytomX Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of CytomX Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 116.4 M | 122.2 M | |
| Pretax Profit Margin | 0.03 | 0.03 | |
| Operating Profit Margin | (0.06) | (0.06) | |
| Net Loss | (0.01) | (0.01) | |
| Gross Profit Margin | 1.02 | 0.99 |
CytomX Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 73.8 M | |
| Quarterly Earnings Growth Y O Y | 0.819 | |
| Forward Price Earnings | 14.2045 |
CytomX Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of CytomX Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value CytomX we look at many different elements of the entity such as CytomX's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as CytomX Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use CytomX Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes CytomX Therapeutics' worth.Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.